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Biobank research has been the focus of great interest of scholars and regulatory bodies who have addressed different ethical issues.
On the basis of a review of the literature it may be concluded that, regarding some major themes in this discussion, a consensus
seems to emerge on the international scene after the regular exchange of arguments in scientific journals. Broad or general consent is
emerging as the generally preferred solution for biobank studies and straightforward instructions for coding will optimise privacy while
facilitating research that may result in new methods for the prevention of disease and for medical treatment. The difficult question
regarding the return of information to research subjects is the focus of the current research, but a helpful analysis of some of the
issues at stake and concrete recommendations have recently been suggested.
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The use of human tissue material in combination with information
about disease history and life style in biomedical research has
attracted a lot of interest by biomedical scientists, philosophers,
lawyers, and different regulatory bodies. The scholarly literature as
well as the number of ethical guidelines and legal rules intended to
govern biobank research has increased rapidly during the last 10
years. Samples collected for the study of a specific disease should
be distinguished from large population studies where samples are
collected for future use. However, in practice, the difference
between collections may not be so great as samples within the first
category may later become of interest for other kinds of studies.
The major moral concerns are related to (i) the selection of
appropriate information and consent procedures for different
research protocols, (ii) the protection of confidentiality of those
who submit tissue material or personal information while still
facilitating important research, and (iii) how to handle research
results or incidental findings that is of potential interest to the
donors or to their genetic relatives. Regarding these themes
different arguments have been proposed and challenged to an
extent that it is now possible to see the beginning of a concordance
related to some important positions. I will, in this review,
concentrate on this emerging trend, but I will start by going
through some of the questions in the current debate.
DOES BIOBANK RESEARCH IMPLY NEW ETHICAL
CHALLENGES?
It has been claimed that biobank research gives rise to new ethical
challenges, ‘many of which test our traditional legal concepts,
governance provisions and bioethical principles’ (Gibbons and
Kaye, 2007, p 204). However, research ethics committees have a
rather long experience in balancing interests regarding the
collection of sensitive information into databases and the use of
genetic information and family history in association with genetic
epidemiologic research. It seems to be a well-established and
approved practice to select different information and consent
procedures for different research protocols (Council of Europe,
1997, Commentary 137 to Article 22; Hansson, 1998), and most
countries have national medical registries with sufficient protec-
tion of confidentiality, sometimes without the need of individual
consent, for example national cancer registries. As Chadwick and
Cutter (2007, p 225) have noted:
Arguably, since Gregor Mendel’s original experiments with the
hereditary characteristics of pea plants, through to James
Watson and Francis Crick’s identification of the double helix of
DNA, the biological sciences have been on a trajectory that
seems naturally to culminate in the creation of human genetic
research databases or biobanks.
However, even if this may be seen as a natural development,
ethical review boards have to deal with new kinds of challenges
related to biobank studies that has not been thoroughly reflected in
existing guidelines; for example, the selection of an appropriate
information and consent procedure for future use of biobank
samples, questions about coding of samples and medical data, and
the question whether research results should be returned or not
(c.f. Auray-Blais and Patenaude, 2006).
IN WHAT SENSE IS PUBLIC TRUST AT STAKE?
Public trust is a major concern in association with biobank
research. Decreased confidence in biobanking practice may have
damaging consequences. If individuals start revoking their
consents the banks will not be complete, the possibility to draw
scientifically valid conclusions will decrease, and the potential for
follow-up examinations and medical treatment will not be fulfilled.
In practice, the notion of public trust is a complex phenomenon.
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‘publics’ whose trust may be at stake. In an interview study with
children and families in paediatric oncology, they found what they
called a ‘hybrid social world’, where the patients and their families
felt themselves to be in alliance with the nurses, doctors,
and scientists. They shared a common goal of providing new
treatment opportunities for children with cancer. They were
grateful for contributions to science made by earlier patients and
were positive to donate samples and give access to medical data in
order to benefit future patients. As Dixon-Woods et al conclude,
this sense of public trust within a community of scientists and
patients stands in sharp contrast to a common view where
scientists and the public stand in opposition to each other,
portraying a picture where the public feel ‘disenfranchised from,
and disempowered by, the modern machinery of researchy’
(Laurie, 2002, p 311).
Patient groups represent an important part of the general public
because they have an experience of participating in research and
they are directly concerned by providing samples and information.
As witnessed in the study by Dixon-Woods et al, they have also a
strong sense of solidarity with future patients. However, one
should not underestimate the role of the general public and the
vulnerability of trust at this level. There is a risk that damaged
trust in one area related to medical practice and research may
affect other areas as well. On example of this is the organ retention
controversy in the United Kingdom that led to the UK Human
Tissue Act in 2004, a regulation that has been questioned as not
entirely appropriate for biobank research (McHale et al, 2007).
It has been suggested that special governance frameworks
should be created to promote public trust (Caulfield et al, 2003;
Cambon-Thomsen et al, 2007) and the UK Biobank established
accordingly a separate ethics and governance council with this end
in mind. Public trust is also believed to require different
participatory approaches so that donors of tissue material should
have control over how their specimens and data are used and for
what purposes. Wolf and Lo (2004) have suggested that ‘tiered
consent’, where the donor may permit only some use and require
renewed consent for other studies, is a preferable instrument to
promote participation. However, this approach is problematic for
several reasons.
It should first be observed that ethical review boards and
regulatory bodies setting up rules for biobank research are
themselves subjects to public trust. Patients and healthy donors
have interests at the beginning of the research line, for example
being assured about the protection of their integrity and providing
tissue material and access to personal data for good scientific
reasons, but they have also research interests connected to the
potential of providing new treatment and new medical products
(Hansson, 2005). On account of long lead times in biomedical and
pharmaceutical research, they may not reap a benefit from the
actual study but a too strict interpretation of the legal principles
governing this kind of research, for example regarding the
possibility to use earlier collected samples without a renewed
consent, may be detrimental to their general research
interests. Under the condition that both the initiation of a new
biobank and each new research project emanating from this
biobank are examined by the ordinary ethics review boards, there
seem to be no need of extra independent governance bodies. Their
mandate is unclear, with members often elected by parties directly
involved in the biobank effort. For the scientists, they create a new
bureaucratic level and they cost money that could be used for
research.
Moreover, as argued by Campbell (2007, p 242), to safeguard
altruism and trust in biobank research, one should refrain from
‘suggesting that individual donors have ongoing rights to exercise
control over uses of their donated materials and the resource
itself’. This point has been emphasised also by Shickle (2006,
p 516): ‘Providing that there is proper disclosure and so on, then
the choice for the individual is to participate on the terms offered
or not. There is a ‘negative right’ not to be included in the research
without consent y There is no ‘positive right’ for a biobank to be
run in such a way just because an individual would like it to be so’.
MOVING TOWARDS BROAD CONSENT TO BIOBANK
SAMPLING
The selection of appropriate information and consent procedures
in association with biobank research has been one of the most
contested issues. There are advocates both of an explicit and
specified consent for research (Greely, 2007) as well as those
critical of the ‘fetishisation’ of consent as the ethical arbiter in
biobanking (Laurie, 2008). In support of the last view, Knoppers
and Chadwick (2005) have identified a new trend in ethics, where
solidarity and reciprocity are guiding ethical principles. They
suggest that this ‘symbolize not only a move away from autonomy
as the ultimate arbiter y but also an appreciation of the need for a
participatory approach’ (ibid p 75). This proposal seems to go
against a long and well-established tradition in medical research
ethics, where ideas about the respect for patients’ autonomous
decisions and their right to say no or to withdraw their consent are
vital interests. However, respect for autonomy may still be seen as
the basic concern regarding which ideas about solidarity and
reciprocity could be developed. The conception of autonomy may
arguably in itself include the participatory approach that Knoppers
and Chadwick seek.
According to a common view, autonomy is a political concept
that basically derives from the ancient world where an individual
was autonomous when he took charge of his own affairs, protected
from external interference. In contrast to this tradition, Kant
defined autonomy as a moral concept (Hansson, 2008). Respect for
people’s autonomy entails, according to Kant, a respect for their
capacity to participate in the formulation of the moral principles
that every human being would wish to endorse. Making
autonomous decisions in accordance with the Kantian tradition
thus involves taking into account of the well-being of others
through a judgment of how one’s own decisions affect other
people’s ability to act in a morally responsible way and to attain
their own goals. Autonomy in the Kantian tradition is inherently
social, with the implication that the working out of legal
protections for self-determination and privacy in association with
biobank research must simultaneously do justice to both the
research subject’s independence and to this individuals’ depen-
dence on others for fulfilling mutual interests such as new
biomedical knowledge and new treatment opportunities.
As a consequence, several information and consent procedures
may be available, which all are legitimate. Respect for autonomy
does not automatically lead to the requirements of specific
consents, as argued by McQuillan et al (2003). From the
perspective of the Kantian view on moral autonomy where the
individual is called upon to take also other individual’s
interests into consideration (for example, future members of
society), it may be sufficient if there is a democratic instrument
available that ensures the individual citizen insight into how the
biobank is organised and that principles for balancing of
interests at the ethical review boards take all relevant interests
into account.
Caulfield (2007) has recently argued against general consent.
This has for some time been regarded as the ‘American’ position in
comparison with the ‘European’ position, which early on moved
towards more general information and consent procedures (Elger
and Caplan, 2006). Elger and Caplan suggest now that general
consent should be the international standard. The European
Council has recently in a draft memorandum taken the view that
broad consent to future research use is acceptable (Council of
Europe, 2006). This view is shared by several commentators who
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Thomsen et al, 2007; Haga and Beskow, 2008). The move towards
broad or general consent is supported both by empirical surveys
and by philosophical arguments (Hansson et al, 2006; Wendler,
2006).
According to this view, a general or broad consent is also an
informed consent. This understanding has been contested by some
(A ´rnason, 2004; Caulfield, 2007; Greely, 2007). A ´rnason (2004,
p 41) argues that
If we are to preserve a meaningful notion of informed consent
for participation in research, it should only be used about
specified research where the participants are informed about
the aims and methods of a particular research proposal. y
There is no such thing as ‘general informed consent’. The more
general the consent is, the less informed it becomes. It is
misleading to use the notion of informed consent for
participation in research that is unforeseen and has not been
specified in a research protocol.
However, the success of biobank research implies that
large repositories of human tissue material are collected together
with well-described and managed clinical and personal data.
‘Biobanks’ represent a wide spectrum of such repositories with
associated data, from small clinical sample collections to large
research infrastructures with hundreds of thousands of samples.
They share nevertheless one characteristic feature. A small biobank
can be reused for another purpose as the scientific knowledge
develops, and large biobank research platforms are intended for
unspecified broad research use in the future. The specific nature of
the research is unknown and only general descriptions about the
goals of these biobanks are possible, for example for biomedical
research or research on diagnose groups. A specific consent to a
narrowly described research protocol is not possible and there is a
need to ask for a broad or general consent covering future
research.
Caulfield and A ´rnason argue that the traditional meaning of
informed consent cannot accommodate these broad and future
consents. Consent should be based on specific information,
otherwise it is not a valid consent. However, as we in our research
team have pointed out earlier, this only begs the question: ‘What is
appropriate information? If the information covers all aspects
relevant for a person’s choice, then that person’s consent is
appropriately informed. If the essential risk and benefit levels are
general to a number of studies, then general information on these
studies may be sufficient for the donor of the sample to make an
informed decision’ (Hansson et al, 2006, p 266). The appearance of
several large population-based biobanks in several countries
indicates that it is possible to inform about the importance of
these research platforms with only general purposes describable. It
should be observed that broad or general consent does not imply
‘blanket’ consent to all uses. In agreement with legislation in many
countries, the consent refers to use in biomedical research, not to
other kinds of uses, for example for forensic use, for investigations
of parenthood, or for use by immigration authorities. Biological
research in the area of medicine may arguably be of use for many
purposes outside medicine and the health-care sector. However,
these applications need to be handled by other regulatory
frameworks.
CODING TO PROTECT PRIVACY
‘Consent or anonymise’ have for long been the accepted ethical
position (Laurie, 2008). However, from a scientific point of view,
anonymisation is not a viable alternative for the major bulk of
research coming up on gene–environment interaction. The
potential of a biobank lies in the possibility to link genetic
and biologic data to medical and personal information, and to
re-contact donors in order to update this information. Anonymi-
sation has even been regarded as disrespectful to participants
(Eriksson and Helgesson, 2005). There is a great variation in the
terminology used for protecting privacy. This has been suggested
as one of the chief obstacles to successful international collabora-
tion in biobank research by Knoppers et al (2007). They have
argued that in the absence of ‘common y norms, laws and
approaches within a properly harmonised international frame-
work, international collaboration will remain an empty platitude’
(p 311). This is a doubtful position considering the great number
of already ongoing successful international collaborations using
biobank material. As mentioned by Knoppers et al in this article,
the Public Population Project in Genomics (P
3G) is an example of
an effort to provide an international Charter while respecting a
diversity of national frameworks. There are also regulatory
principles already in place.
There is a common understanding of laws for personal data
protection that, with some exceptions, it is the individual who has
the right of disposition of sensitive personal information. This
implies that the patient/donor has the sovereign right to decide if
and how personal data and tissue material may be used; for
example a ‘yes’ to the use of personal data must be respected by an
ethical review board and by the data protection authorities. These
authorities may in some instances grant permission to do research
using sensitive data without consent from the donor. However, the
individual has normally the right to grant such use. This implies
that it is essential that the information include possible uses of
personal data associated with a research project or the collection of
human tissue samples, as well as the measures taken to protect the
privacy of the individual donors. It may, for example, include
information that genetic analyses will be performed and that
international collaboration takes place, which implies the transfer
of biological material and data across borders. If the research will
or may involve commercial partners and interests, for example
future patenting, this may also be included in the information. It is
then up to the participant to decide if he or she wants to
participate on those terms.
To evade the terminological difficulties, the European
authority for supervision of pharmaceutical research (EMEA,
2002) has suggested a nomenclature that seems to fit the
needs of current research practice and is in line with the ambitions
of different harmonising projects to optimise privacy. They
recommend that regarding anonymous samples, there are no links
to the individual donor (although there may be general descrip-
tions such as ‘man, aged 50–55 years, cholesterol level 4240mg
per 100ml’). Identified samples are linked to the individual in a
way that makes them immediately identifiable. A simple code is a
direct link to the individual, usually through a random set of
numbers or letters, or a bar code. A double code implies that to
link the sample and the data to the individual, a second code is
needed. Anonymised samples are those that have been identified
earlier or coded but the identification, or the code and the code key
have been destroyed, and thus there is no longer any link to the
individual.
The International Conference on Harmonisation of Technical
Requirements (ICH) has now (1 November 2007) adopted this
nomenclature for the Registration of Pharmaceuticals for Human
Use (ICH Harmonised Tripartite Guideline, 2007). The ICH brings
together the regulatory authorities of Europe, Japan, and the
United States. In the European Union, the Committee for Human
Medical Products has endorsed the guidelines, which came into
operation in May 2008. The guidelines are made available by the
US Food and Drug Administration and by the Pharmaceutical and
Medical Safety Bureau in Japan. Taking this recent development
into consideration, this nomenclature may now be seen as a
significant part of an international Charter regarding coding of
human biosamples and data for the protection of privacy of donors
donating samples for research.
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As observed by Cambon-Thomsen (2004), the individual partici-
pant in a biobank study will typically not benefit by participating.
The purpose is to provide knowledge that may benefit a specific
disease group or the population at large. This is the common
feature of the majority of medical research. Even national
population biobanks will have the world population as aimed
beneficiaries, rather than their own citizens. A feature of several
national legislations is that human body and tissue material cannot
be owned or sold. Haga and Beskow (2008, p 526) noted that a
Florida court in 2003 (Greenberg v. Miami Children’s Hospital
Research Institute, Inc.) ‘reaffirmed the Moore decision by
unambiguously stating that individuals do not have ownership
rights in specimens donated for research purposes’. Private
benefits are then not available for participants, but there may be
either research results or incidental findings that may be of interest
to them.
Information about research results of a biobank study is made
available through publication in scientific journals. Specific
information to individual donors is generally not advisable as it
implies assuming a responsibility for the clinical significance for
an individual based on information about the odds ratio
expressing risk only for a study population. Research groups
may not be equipped for assuming such a responsibility.
Communicating genetic information implies skills in genetic
counselling and the information may be of direct concern to
genetic relatives who also must be informed. ‘Misinterpretation
can cause potential psychological, social, and economic harm –
especially before validation of the clinical significance of the
findings. This is particularly true if no relevant treatment or
prevention modality to combat the investigated risk is yet
available’ (Helgesson et al, 2007, p 975). If clinically significant
findings are expected to emanate from the research, this implies
that a close collaboration has to be set up from the start together
with clinical departments and wards that can provide counselling
and advice about treatment. There may be different policies for
handling research results and handling incidental findings in
research even if the clinical significance (clinical validity and
clinical utility) may be a common denominator for these
policies. Recent recommendations regarding how incidental
findings should be handled provides a good start for this
policymaking.
In a report from a symposium on the management of incidental
findings, Wolf et al (2008) have provided a helpful analysis with
some central recommendations. They define an incidental finding
(IF) as such: ‘An IF is a finding concerning an individual research
participant that has potential health or reproductive importance
and is discovered in the course of conducting research but is
beyond the aims of the study.’ (p 219) The fundamental idea is that
the researcher already in the information to the donor/patient
should explain how incidental findings of likely health or
reproductive importance will be handled. A model for manage-
ment of these findings will then include collaboration with relevant
clinical expertise from the start and preparation of a disclosure
scheme depending on the expected net benefits for the individual
participant.
CONCLUSION
With broad consent emerging as the generally preferred solution
for biobank studies and simple instructions available for coding
that will protect the privacy of donors there is a good climate for
international collaboration that may make progress in biobank
research for the benefit of future patients through prevention and
treatment. The ethical review boards will play a key role in
balancing interests associated with different research protocols.
Regarding incidental findings a helpful start has recently been
provided.
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